BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

05/14/2026, 1:51 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

05/06/2026, 9:14 PM • GlobeNewswire

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm

The Schall Law Firm is investigating potential breaches of fiduciary duty by XOMA Royalty Corporation's board and management regarding the company's $739 million acquisition by Ligand Pharmaceuticals. Shareholders are invited to participate in the investigation.

04/28/2026, 5:40 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four pharmaceutical and real estate companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

04/27/2026, 9:23 PM • GlobeNewswire

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million ($39.00 per share in cash). The deal is expected to be immediately accretive to adjusted EPS and increases Ligand's 2026 guidance to $8.50-$9.50 per share, with an additional $1.50 per share contribution expected in 2027. The acquisition expands Ligand's royalty portfolio and strengthens its position as a leading biopharma royalty aggregator.

04/27/2026, 1:18 PM • Benzinga

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)

Monteverde & Associates PC announced investigations into multiple companies involved in M&A transactions, including XOMA Royalty Corporation's proposed sale to Ligand Pharmaceuticals at $39.00 per share in cash. The firm is examining whether the deal terms are fair to shareholders.

04/27/2026, 10:58 AM • GlobeNewswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Miluna Acquisition Corp. (NASDAQ: MMTX)

Monteverde & Associates PC, a class action securities firm, has announced investigations into Miluna Acquisition Corp. (MMTX) regarding its merger with CADV Ventures S.A., as well as investigations into XOMA Royalty Corporation (XOMA) and Helix Energy Solutions Group, Inc. (HLX). The firm is seeking shareholders with concerns about potential fairness issues in these transactions.

04/27/2026, 10:55 AM • GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals announced it will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. The acquisition expands Ligand's royalty portfolio to over 200 assets and adds seven commercial products. Ligand raised its 2026 adjusted EPS guidance to $8.50-$9.50 and expects the transaction to be accretive by $1.50 per share in 2027. The deal is expected to close in Q3 2026.

04/27/2026, 7:00 AM • Benzinga

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about April 15, 2026, to shareholders of record as of April 2, 2026.

03/18/2026, 4:30 PM • Benzinga

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

03/18/2026, 6:00 AM • GlobeNewswire

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

XOMA Royalty Corporation successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash plus one contingent value right. Approximately 70% of Generation Bio's outstanding shares were validly tendered by the February 6, 2026 expiration date, satisfying the minimum tender condition. Following the acquisition, Generation Bio became a wholly owned subsidiary of XOMA Royalty and ceased trading on Nasdaq.

02/09/2026, 9:53 AM • Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital hyperinsulinism. XOMA's stock fell 22.76% on the news.

01/20/2026, 4:47 PM • GlobeNewswire

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about January 15, 2026, to shareholders of record as of January 2, 2026.

12/22/2025, 7:30 AM • Benzinga

XOMA Royalty Enters into Agreement to Acquire Generation Bio

XOMA Royalty Corporation announced an agreement to acquire Generation Bio for $4.2913 per share, with additional contingent value rights for stockholders. The acquisition is expected to close in February 2026 and includes potential milestone and royalty payments.

12/15/2025, 5:00 PM • GlobeNewswire

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.

12/05/2025, 7:45 AM • Benzinga